Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 1, 2014, Pages 69-78

  Kolkhof, Peter ^a   Delbeck, Martina ^a   Kretschmer, Axel ^b   Steinke, Wolfram ^c   Hartmann, Elke ^d   Bärfacker, Lars ^e   Eitner, Frank ^a   Albrecht Küpper, Barbara ^a   Schäfer, Stefan ^b  

^a Department of Cardiology Research Global Drug Discovery Bayer Health Care ^*  (Germany)

^b Clinical Sciences Bayer HealthCare   (Germany)

^c Drug Metabolism and Pharmacokinetics Bayer HealthCare   (Germany)

^d Toxicology   (Germany)

^e Medicinal Chemistry   (Germany)

Author keywords

chronic kidney disease; heart failure; hypertrophy; remodeling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DEOXYCORTICOSTERONE ACETATE; EPLERENONE; FINERENONE; MINERALOCORTICOID ANTAGONIST; NAPHTHYRIDINE DERIVATIVE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIORENAL INJURY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ELECTROLYTE DISTURBANCE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEAT INJURY; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RADIOACTIVITY; RAT; TISSUE DISTRIBUTION; TREATMENT OUTCOME; WHOLE BODY AUTORADIOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; AUTORADIOGRAPHY; BLOOD; CARDIOMEGALY; COMPARATIVE STUDY; DISEASE MODEL; KIDNEY DISEASES; SPRAGUE DAWLEY RAT; WISTAR RAT;

ANIMALS; AUTORADIOGRAPHY; CARDIOMEGALY; DISEASE MODELS, ANIMAL; HEART FAILURE; KIDNEY DISEASES; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NAPHTHYRIDINES; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SPIRONOLACTONE; TISSUE DISTRIBUTION;

EID: 84904267679     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000091     Document Type: Article

References (31)

1. Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730Y1736
2. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J. 1998;19:1552Y1563
3. Delcayre C, Silvestre JS. Aldosterone and the heart: Towards a physiological function?. Cardiovasc Res. 1999;43:7Y12
4. Funder JW. Mineralocorticoid receptors: Distribution and activation. Heart Fail Rev. 2005;10:15Y22
5. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341: 709Y717
6. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309Y1321
7. van den Meiracker AH, Baggen RG, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285Y2292
8. Samuel JL, Delcayre C. Heart failure: Aldosterone antagonists are underused by clinicians. Nat Rev Cardiol. 2010;7:125Y127
9. Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab. 2005;1:4Y5
10. Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics. Mol Cell Endocrinol. 2012;350: 310Y317
11. Bärfacker L, Kuhl A, Hillisch A, et al. Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7:1385Y1403
12. Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail. 2012;14:668Y675
13. Schupp N, Kolkhof P, Queisser N, et al. Mineralocorticoid receptormediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J. 2011;25:968Y978
14. Curtis CG, Cross SAM, McCulloch RJ, et al. Whole-Body Autoradiography. London, New York: Academic Press; 1981
15. Bauersachs J. The ARTS of third-generation mineralocorticoid receptor antagonists: Achieving cardiovascular benefit with minimized renal side effects?. Eur Heart J. 2013;34:2426Y2428
16. Willnow TE, Nykjaer A. Cellular uptake of steroid carrier proteinsY mechanisms and implications. Mol Cell Endocrinol. 2010;316:93Y102
17. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: Characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650Y656
18. Kagawa CM. Blocking the renal electrolyte effects of mineralocorticoids with an orally active steroidal spirolactone. Endocrinology. 1960;67: 125Y132
19. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 2001;281:H647YH654
20. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol. 2003;42:1666Y1673
21. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802YH1810
22. Brandish PE, Forest TW, Chen H, et al. Eplerenone decreases inflammatory foci in spontaneously hypertensive rat hearts with minimal effects on blood pressure. J Cardiovasc Pharmacol. 2009;53:44Y51
23. Brandish PE, Chen H, Szczerba P, et al. Development of a simplified assay for determination of the antimineralocorticoid activity of compounds dosed in rats. J Pharmacol Toxicol Methods. 2008;57:155Y160
24. Schäfer A, Fraccarollo D, Hildemann SK, et al. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: Effect on endothelial dysfunction. Cardiovasc Res. 2003;58:655Y662
25. Fraccarollo D, Galuppo P, Schmidt I, et al. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction. Cardiovasc Res. 2005;67:97Y105
26. Orena S, Maurer TS, She L, et al. PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy. Front Pharmacol. 2013;4:115
27. Inspra Drug Approval Package, 2003. Pharmacological Review Inspra Drug Approval Package 21-437/S-002, FDA US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2003/21-437S002-Inspra- Pharmr.pdf. Accessed March 2014
28. Platt D, Pauli H. Studies on organ-and subcellular distribution of 3Hspironolactone in animals [in German]. Arzneimittelforschung. 1972;22: 1801Y1802
29. Hildebrand M, Krause W, Kühne G, et al. Pharmacokinetics and metabolism of mespirenone, a new aldosterone antagonist, in rat and cynomolgus monkey. Xenobiotica. 1987;17:623Y634
30. García NH, Baigorria ST, Juncos LI. Hyperkalemia, renal failure, and converting-enzyme inhibition: An overrated connection. Hypertension. 2001;38:639Y644
31. Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J. 2013;34:2453Y2463